Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) is -61.76% lower on its value in year-to-date trading and has touched a low of $0.22 and a high of $1.65 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ADAP stock was last observed hovering at around $0.22 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.21, the stock is -47.47% and -59.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.96 million and changing -6.36% at the moment leaves the stock -74.63% off its SMA200. ADAP registered -86.45% loss for a year compared to 6-month loss of -77.59%. The firm has a 50-day simple moving average (SMA 50) of $0.50534 and a 200-day simple moving average (SMA200) of $0.811925.
The stock witnessed a -62.62% gain in the last 1 month and extending the period to 3 months gives it a -64.41%, and is -29.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.66% over the week and 12.74% over the month.
Adaptimmune Therapeutics Plc ADR (ADAP) has around 506 employees, a market worth around $52.72M and $178.56M in sales. Profit margin for the company is -39.31%. Distance from 52-week low is -6.17% and -87.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-86.30%).
with sales reaching $7.05M over the same period.The EPS is expected to shrink by -56.09% this year, but quarterly earnings will post -75.94% year-over-year. Quarterly sales are estimated to grow 24.19% in year-over-year returns.
Adaptimmune Therapeutics Plc ADR (ADAP) Top Institutional Holders
94.0 institutions hold shares in Adaptimmune Therapeutics Plc ADR (ADAP), with institutional investors hold 49.74% of the company’s shares. The shares outstanding are 255.94M, and float is at 226.52M with Short Float at 2.49%. Institutions hold 49.59% of the Float.
The top institutional shareholder in the company is MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares valued at $38.0 million. The investor’s holdings represent 2.5415% of the ADAP Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 27.4 million shares valued at $26.72 million to account for 1.787 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 17.08 million shares representing 1.1138% and valued at over $16.65 million, while BAILLIE GIFFORD & CO holds 0.9879 of the shares totaling 15.15 million with a market value of $14.77 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
The most recent transaction is an insider sale by Norry Elliot, the company’s Chief Medical Officer. SEC filings show that Norry Elliot sold 5,584 shares of the company’s common stock on Jan 17 ’25 at a price of $0.58 per share for a total of $3243.0. Following the sale, the insider now owns 7510.0 shares.
Adaptimmune Therapeutics Plc ADR disclosed in a document filed with the SEC on Jan 17 ’25 that Lunger John (Chief Patient Supply Officer) sold a total of 5,584 shares of the company’s common stock. The trade occurred on Jan 17 ’25 and was made at $0.58 per share for $3243.0. Following the transaction, the insider now directly holds 7510.0 shares of the ADAP stock.
Still, SEC filings show that on Jan 17 ’25, Bertrand William C JR (Chief Operating Officer) disposed off 5,584 shares at an average price of $0.58 for $3243.0. The insider now directly holds 7,510 shares of Adaptimmune Therapeutics Plc ADR (ADAP).
